Literature DB >> 12469210

Cardiomyopathy: molecular and immunological aspects (review).

Nobuakira Takeda1.   

Abstract

Idiopathic cardiomyopathy is reviewed from molecular standpoint. About a half of all patients with hypertrophic cardiomyopathy show intra-familial occurrence. In familial hypertrophic cardiomyopathy, nine gene abnormalities have been discovered in the sarcomere, i.e. the genes of beta cardiac myosin heavy chain, cardiac troponin T, alpha-tropomyosin, cardiac myosin binding protein-C, essential or regulatory myosin light chain, cardac troponin I, alpha-cardiac actin, and titin. Sudden death can occur in patients with familial-type hypertrophic cardiomyopathy with abnormalities of the cardiac troponin T or troponin I gene, even if hypertrophy is not marked. Some cases of familial dilated cardiomyopathy show gene abnormalities for cytoskeletal components such as desmin and laminin A/C. Mutations of the delta-sarcoglycan gene have also been discovered in familial or sporadic dilated cardiomyopathy. Mutations in mitochondrial genes have been observed in both hypertrophic and dilated cardiomyopathy. It is postulated that chronic viral myocarditis may sometimes lead to dilated cardiomyopathy, and hepatitis C virus is also thought to be an etiological factor. Immunological abnormalities have also been reported, such as autoantibodies against myosin, beta-receptors, ADP/ATP carrier proteins.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12469210

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  10 in total

Review 1.  Myofibrillar remodeling in cardiac hypertrophy, heart failure and cardiomyopathies.

Authors:  Jarmila Machackova; Judit Barta; Naranjan S Dhalla
Journal:  Can J Cardiol       Date:  2006-09       Impact factor: 5.223

2.  Hypertrophic cardiomyopathy in systemic sclerosis. A report of two cases.

Authors:  I Moyssakis; D P Papadopoulos; G Anastasiadis; P Vlachoyannopoulos
Journal:  Clin Rheumatol       Date:  2005-10-12       Impact factor: 2.980

3.  Intermediate filament diseases: desminopathy.

Authors:  Lev G Goldfarb; Montse Olivé; Patrick Vicart; Hans H Goebel
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

4.  Hypertrophic obstructive cardiomyopathy in rheumatoid arthtritis - coincidence or association? A case report.

Authors:  I Moyssakis; N Lionakis; V Votteas
Journal:  Exp Clin Cardiol       Date:  2009

5.  HBEGF, SRA1, and IK: Three cosegregating genes as determinants of cardiomyopathy.

Authors:  Frauke Friedrichs; Christian Zugck; Gerd-Jörg Rauch; Boris Ivandic; Dieter Weichenhan; Margit Müller-Bardorff; Benjamin Meder; Nour Eddine El Mokhtari; Vera Regitz-Zagrosek; Roland Hetzer; Arne Schäfer; Stefan Schreiber; Jian Chen; Isaac Neuhaus; Ruiru Ji; Nathan O Siemers; Norbert Frey; Wolfgang Rottbauer; Hugo A Katus; Monika Stoll
Journal:  Genome Res       Date:  2008-12-08       Impact factor: 9.043

6.  Tropomyosin flexural rigidity and single ca(2+) regulatory unit dynamics: implications for cooperative regulation of cardiac muscle contraction and cardiomyocyte hypertrophy.

Authors:  Campion K P Loong; Myriam A Badr; P Bryant Chase
Journal:  Front Physiol       Date:  2012-04-04       Impact factor: 4.566

7.  Association of Hypertrophic Obstructive Cardiomyopathy with Rheumatoid Arthritis.

Authors:  Mustafa Dawood; Noman Lateef; Abubakar Tauseef; Janki Patel
Journal:  Cureus       Date:  2018-01-05

Review 8.  From stem cells to cardiomyocytes: the role of forces in cardiac maturation, aging, and disease.

Authors:  Gaurav Kaushik; Adam J Engler
Journal:  Prog Mol Biol Transl Sci       Date:  2014       Impact factor: 3.622

Review 9.  Acute viral myocarditis.

Authors:  Robert Dennert; Harry J Crijns; Stephane Heymans
Journal:  Eur Heart J       Date:  2008-07-09       Impact factor: 29.983

10.  TNF-alpha-mediated signal transduction pathway is a major determinant of apoptosis in dilated cardiomyopathy.

Authors:  Samarjit Das; Andrea P Babick; Yan-Jun Xu; Nobuakira Takeda; Delfin Rodriguez-Levya; Naranjan S Dhalla
Journal:  J Cell Mol Med       Date:  2009-09-14       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.